SCHEMBL5074835

SCHEMBL5074835

O=C(NCCOc1ccccc1)c1cc(F)ccc1NS(=O)(=O)c1cccc2cccnc12

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FABP1 P07148 2/20 0.54
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 2/20 0.50
MAPT P10636 1/20 0.50
HPGD P15428 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
KCNA5 P22460 1/20 0.50
POLB P06746 2/20 0.48
GAA P10253 1/20 0.48
SLC40A1 Q9NP59 3/20 0.47
MMP2 P08253 1/20 0.47
PKLR P30613 3/20 0.47
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
SLC16A3 O15427 1/20 0.46
PGAM1 P18669 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137615 0.89 MEN1 (0.49) FABP1MEN1KMT2AALDH1A1MAPT
SCHEMBL498858 0.83 MMP2 (0.60) MEN1KMT2AALDH1A1KCNA5POLB
SCHEMBL14392443 0.79 KCNA5 (0.62) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL5075476 0.79 KCNA5 (0.80) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL498647 0.79 KCNA5 (0.80) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL498394 0.79 KCNA5 (0.80) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL5616220 0.79 MEN1 (0.47) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL5072760 0.79 MEN1 (0.59) FABP1MEN1KMT2AALDH1A1MAPT
SCHEMBL498369 0.78 KCNA5 (0.79) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL498368 0.78 KCNA5 (0.79) MEN1KMT2AALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399423-B9 ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS SANOFI AVENTIS DEUTSCHLAND (DE) 2008-02-27 EP disclosed
EP-1399423-B1 ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS SANOFI AVENTIS DEUTSCHLAND (DE) 2007-11-14 EP disclosed
US-7235664-B2 Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-7235664-B2 Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-7235664-B2 Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-26 US disclosed
US-20050137200-A1 Potassium channel modulators; antiarrhythmia agents AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-23 US disclosed
US-6903216-B2 Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-07 US disclosed
EP-1399423-A2 ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT OR DIAGNOSTIC AGENT AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS Aventis Pharma Deutschland GmbH (DE) 2004-03-24 EP disclosed
US-20030114499-A1 Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-06-19 US disclosed
WO-2002100825-A2 ANTHRANILIC ACID AMIDES WITH A HETEROARYLSULFONYL SIDE CHAIN, AND USE THEREOF AS ANTIARRHYTHMIC ACTIVE SUBSTANCES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137200-A1 Potassium channel modulators; antiarrhythmia agents KCNJ2, KCNQ5, KCNH1 FABP1 3510/4885MEN1 3672/4885KMT2A 185/4885
US-20030114499-A1 Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use KCNJ2, KCNQ5, KCNH1 FABP1 3419/4885MEN1 3688/4885KMT2A 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.